Diabetes Drugs and Cardioprotection: 8 Questions on Key Trials

What is Driving Type 2 Diabetes in the US?

News

Slideshow

Find out what you know about which diabetes drugs in which classes show CV protective properties and results of the trials that support their use.

Related Content

July 22nd 2025

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Type 2 diabetes and its high and rising rates in the US are the result of a perfect storm of converging systemic, behavioral, environmental, and economic factors.

FDA Approves Finerenone for Heart Failure With LVEF ≥40% Following Positive Phase 3 Data

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

July 14th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.

August 30th 2023

Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

BF% outperforms BMI in Predicting Morality risk in young adults: New Findings / image courtesy of University of Florida

Novel GLP-1/GLP-2 Agent Reduces Body Weight by Up to 8.3% in Phase 1b Obesity Trial

Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.

July 7th 2025

What is Driving Type 2 Diabetes in the US?

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.

Related Content

July 22nd 2025

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Type 2 diabetes and its high and rising rates in the US are the result of a perfect storm of converging systemic, behavioral, environmental, and economic factors.

FDA Approves Finerenone for Heart Failure With LVEF ≥40% Following Positive Phase 3 Data

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

July 14th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.

August 30th 2023

Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Novel GLP-1/GLP-2 Agent Reduces Body Weight by Up to 8.3% in Phase 1b Obesity Trial

Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.

July 7th 2025